

## ANSWERING REVIEWERS

Dear Editor,

We have revised the manuscript as suggested by the reviewers. The revision have been highlighted in the manuscript and mentioned below:

**Reviewer 1:**

1. This review presented a rare liver tumor, combined hepatocellular-cholangiocarcinoma. This manuscript was relatively well- organized, and informative. As the authors stated, the definition of combined hepatocellular-cholangiocarcinoma has not been fully clear. It was assumed that pathological features were important for the differentiation of CHC from HCC and CC. Pathological features should be described in detail. This pathological information would help to understand Figure 1 A to D.

**Answer:** More detailed pathology descriptions have been added in the manuscript.

2. Origination of CHC from stem cells was an interesting point. Were there any photos available of immunostaining of CHC with antibody to stem cell markers, suggesting that CHC originated from stem cells?

**Answer:** Pictures of the immunohistochemical stains are added.

3. How was the origin of the figures? Were they obtained in the authors' institute? The origin should be clear. Figure 1 B. The photo seemed ordinal HCC. Figure 1 C and D seemed familiar as HCC. Figure 1 C and D looked very similar. Were there any photos available that clearly showed that they were combined hepatocellular-cholangiocarcinoma? For example, how was immunostaining?

**Answer:** All pictures are from our institution and our collaborator institutions. More H&E pictures and immunohistochemical stain pictures are added to clarify different subtypes.

We appreciate the reviewers' constructive comments and suggestions. Please let me know if you have any other comments or suggestions.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Ruliang Xu'.

Ruliang Xu, MD., PhD.